Cbdmd Inc. Earnings Call Signals Cautious Recovery

Cbdmd INc ((YCBD)) has held its Q1 earnings call. Read on for the main highlights of the call.

Cbdmd Inc.’s latest earnings call carried a tone of cautious optimism, as management balanced improving sales trends and near-breakeven EBITDA against softer year-over-year metrics and persistent regulatory uncertainty. Executives stressed that operational progress, a stronger balance sheet, and a strategic acquisition are laying groundwork for a more sustainable recovery, even as execution risks remain.

Sequential Revenue Recovery

Net sales for Q1 FY 2026 came in at about $5.0 million, up 12% from the prior quarter and marking the company’s third straight period of sequential growth. Management highlighted that December 2025 and January 2026 delivered the highest monthly revenue since 2022, signaling a clear rebuild in top-line momentum after a protracted slump.

Channel Mix and Wholesale Momentum

Direct-to-consumer remains the engine of the business, generating roughly 72% of revenue in the quarter and underscoring the strength of the company’s online and direct channels. Wholesale, while smaller at about 28% of sales, grew approximately 17% quarter over quarter, reflecting better execution in the core cbdMD line and early traction from the Oasis beverage brand.

Strategic Acquisition of Bluebird Botanicals

In mid-January, cbdMD closed the acquisition of select assets of Bluebird Botanicals, a move aimed at adding incremental revenue, a loyal customer base, and valuable intellectual property. Management said the deal, structured with limited upfront equity and an earn-out tied to performance, should broaden the wellness portfolio and deliver both cost and revenue synergies at attractive contribution margins.

Improved Capital Structure and Liquidity

The company reported regaining listing compliance and completing roughly $2.25 million in Series C preferred financing in December, shoring up its capital base. Cbdmd ended the quarter with about $3.3–$3.4 million in cash, approximately $5.4 million in working capital, and a $20 million equity line of credit, giving management flexibility to fund growth and integration initiatives.

Per-Share Loss Improvement and Near-Breakeven EBITDA

Net loss attributable to common shareholders narrowed to about $325,000, or $0.04 per share, compared with roughly $1.0 million, or $1.73 per share, a year earlier, largely due to preferred stock conversions. On an adjusted non-GAAP basis, EBITDA loss was just around $36,000, suggesting the company is approaching breakeven and potentially a pivot toward profitability if trends hold.

Cost and Operational Discipline

Management underscored ongoing efforts to lower fixed costs, streamline operations, and protect margins through a focus on high-velocity products and disciplined customer acquisition. They also plan to extract synergies from the Bluebird integration and indicated that, excluding the acquisition, they aim to avoid another sizable working-capital build in the next quarter.

Regulatory Advocacy and Positioning

Executives addressed the challenging regulatory backdrop but emphasized cbdMD’s strategy of active engagement with policymakers and industry organizations to shape future hemp rules. They highlighted participation in federal programs and stressed that cGMP manufacturing, safety data, and clinical research form a competitive moat as the market evolves toward stricter compliance standards.

Year-Over-Year Revenue Slight Decline

Despite the sequential rebound, Q1 FY 2026 net sales of about $5.0 million were modestly lower than the $5.1 million recorded in the year-ago quarter, a decline of roughly 2%. Management acknowledged that while the trajectory is improving, the company is still working to regain its prior scale and that demand has yet to fully recover to historical levels.

Gross Margin Compression

Gross margin slipped to 60% from 66% in the same quarter last year, a six-point decline attributed to higher warehouse costs and a shift toward wholesale as well as mix and pricing changes. While margins remain relatively healthy for the category, the pressure highlights the need for tight cost control and careful channel management as the company pushes for growth.

Wider Operating Loss

Loss from operations expanded to approximately $286,000 from about $86,000 a year earlier, reflecting the impact of margin compression and operating expense dynamics. The widening operating loss contrasts with the improved per-share net loss and underscores that the company still has work to do in aligning expenses with its current revenue base.

Operating Cash Use and Working Capital Build

Cbdmd used around $812,000 in cash for operating activities in the quarter, driven in part by a roughly $200,000 inventory build and approximately $225,000 increase in prepaid expenses, along with a near $300,000 reduction in payables. Management noted that the first fiscal quarter typically requires heavier working capital, but they do not expect a repeat of this level of build next quarter, excluding acquisition effects.

Regulatory Headwinds and Market Uncertainty

The company pointed to restrictive hemp-related language in pending legislation and recent regulatory shifts as sources of customer confusion, especially regarding packaging and product compliance. These headwinds have weighed on sales and raised compliance costs, and management warned that ongoing uncertainty could continue to affect execution until clearer rules are established.

Top-Line Still Below Historical Peaks

Executives were candid that, even with three consecutive quarters of growth, revenue remains below previous peaks reached earlier in the company’s history. They framed current performance as a rebuilding phase, emphasizing that further scaling is needed to fully leverage fixed costs, maximize operating efficiencies, and deliver more robust earnings.

Forward-Looking Guidance and Priorities

Looking ahead, cbdMD aims to sustain sequential revenue gains from the roughly $5.0 million Q1 base while integrating Bluebird Botanicals to capture cost and revenue synergies. Management reiterated its focus on cost discipline, margin stability, and capital efficiency, with a clear target of achieving positive EBITDA supported by a strengthened balance sheet and available liquidity.

Cbdmd’s earnings call outlined a company in transition, moving from stabilization toward measured growth as it rebuilds sales, tightens operations, and invests selectively through acquisitions. For investors, the story is one of cautious promise: improving trends and better capital footing, tempered by margin pressure, regulatory overhang, and the challenge of climbing back to former revenue highs.